It becomes the case that, for most patients, ongoing treatment is required to maintain their weight loss results
doi: 10.1002/9780470939352 47 SandersonSGreenAPreeceMABurtonH
Here, well be reviewing Cignas coverage for the GLP-1 agonists Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide), including whether prior authorization is needed for coverage and, if so, how to get it
Professor Chris Wilkins, Associate Professor Marta Rychert & Dr Robin van der Sanden, SHORE & Whariki Drug Research Team, comment: What are the biggest health risks of using and self injecting peptides
A nationwide cohort study from Sweden and Denmark found no significant increase in suicide deaths among GLP-1 RA users compared to Sodium-glucose cotransporter-2 (SGLT2) inhibitors, and even reported a lower incidence of combined suicide and self-harm outcomes (HR 0.83) [47]
Varying genetic makeups, microbiomes, metabolic rates, starting BMIs all account for discrepancies amongst patients